PT  - JOURNAL ARTICLE
AU  - Parvathy Radhakrishna Pillai Suma
AU  - Renjini A. Padmanabhan
AU  - Srinivasa Reddy Telukutla
AU  - Rishith Ravindran
AU  - Anoop Kumar G. Velikkakath
AU  - Chaitali D. Dekiwadia
AU  - Willi Paul
AU  - Sachin J. Shenoy
AU  - Malini Laloraya
AU  - Srinivasa M. Srinivasula
AU  - Sheshanath V. Bhosale
AU  - Ramapurath S. Jayasree
TI  - Paradigm of Vanadium pentoxide nanoparticle-induced autophagy and apoptosis in triple-negative breast cancer cells
AID  - 10.1101/810200
DP  - 2019 Jan 01
TA  - bioRxiv
PG  - 810200
4099  - http://biorxiv.org/content/early/2019/10/18/810200.short
4100  - http://biorxiv.org/content/early/2019/10/18/810200.full
AB  - Chemo-resistance remains the main hurdle to cancer therapy, challenging the improvement of clinical outcomes in cancer patients. Therefore, exploratory studies to address chemo-resistance through various approaches are highly rewarding. Nanomedicine is a promising recent advancement in this direction. Comprehensive studies to understand the precise molecular interactions of nanomaterials is necessary to validate their specific “nano induced” effects. Here, we illustrate in detail the specific biological interactions of vanadium pentoxide nanoparticles (VnNp) on triple-negative breast cancer cells and provide initial insights towards its potential in breast cancer management at the cellular level. VnNp shows a time-dependent anti-oxidant and pro-oxidant property in vitro. These nanoparticles specifically accumulate in the lysosomes and mitochondria, modulate various cellular processes including impaired lysosomal function, mitochondrial damage, and induce autophagy. At more extended periods, VnNp influences cell cycle arrest and inhibits cell migration potentiating the onset of apoptosis. Preliminary in vivo studies, on exposing healthy Swiss albino mice to VnNp demonstrated normal blood parameters, organ distribution, and tissue redox balance which further indicated the absence of any adverse organ toxicity. Hence, we foresee tumor-targeting VnNp as a potential drug molecule for future cancer management.